Find Paid Clinical Trials in Georgia

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Georgia

Top of Directory » All Locations » United States » Georgia




  • A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

    Condition:   Acne Vulgaris
    Interventions:   Drug: Tazarotene Foam;   Drug: Vehicle Foam
    Sponsor:   Stiefel, a GSK Company
    Recruiting - verified November 2009

  • Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis

    Condition:   Ulcerative Proctitis
    Interventions:   Procedure: Proctosigmoidoscopy or colonoscopy with biopsy;   Procedure: Proctosigmoidoscopy;   Procedure: Blood collection;   Procedure: Electrocardiogram (ECG);   Drug: MAX-002;   Drug: Canasa®;   Drug: Placebo
    Sponsor:   Axcan Pharma
    Recruiting - verified November 2009

  • A Study With RO4917523 in Patients With Fragile X Syndrome

    Condition:   Fragile X Syndrome
    Interventions:   Drug: RO4917523;   Drug: Placebo;   Drug: RO4917523;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting - verified November 2009

  • Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant

    Conditions:   AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
    Intervention:   Drug: Abatacept
    Sponsor:   Emory University
    Recruiting - verified November 2009

  • A Phase IIb 78-week Study in Patients on a Basal Insulin +/- Metformin and/or Sulfonylurea and Are Not at Goal to Add BI 10773 vs. Placebo

    Condition:   Diabetes Mellitus, Type 2
    Intervention:   Drug: BI 10773
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified November 2009

  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

    Condition:   Melanoma
    Interventions:   Drug: YM155;   Drug: Docetaxel
    Sponsor:   Astellas Pharma Inc
    Recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

    Conditions:   Proctitis;   Proctosigmoiditis
    Interventions:   Drug: Budesonide;   Drug: Placebo
    Sponsor:   Salix Pharmaceuticals
    Not yet recruiting - verified November 2009

  • Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • Study Evaluating Two Dose Levels of Targetin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)

    Condition:   Refractory Cutaneous T-cell Lymphoma
    Interventions:   Drug: bexarotene;   Drug: bexarotene
    Sponsor:   Eisai Inc.
    Not yet recruiting - verified November 2009

  • RSP® Prospective Multi-Center Study

    Conditions:   Rotator Cuff Deficiency;   Shoulder Arthropathy;   Failed Shoulder Replacement
    Intervention:   Device: Encore Reverse Shoulder Prosthesis (RSP®)
    Sponsor:   Encore Medical, L.P.
    Not yet recruiting - verified October 2009

  • A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

    Conditions:   Excessive Daytime Sleepiness;   Narcolepsy
    Interventions:   Drug: Placebo;   Drug: PF-03654746
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents

    Condition:   Acute Migraine With or Without Aura
    Intervention:   Drug: rizatriptan benzoate
    Sponsor:   Merck
    Recruiting - verified November 2009

  • Treatment to Prevent Diabetes Mellitus

    Condition:   Prediabetic State
    Interventions:   Drug: Sitagliptin + Pioglitazone PLACEBO;   Drug: Sitagliptin + Pioglitazone;   Drug: Sitagliptin placebo + Pioglitazone placebo
    Sponsors:   Emory University;   Merck
    Not yet recruiting - verified October 2009

  • TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

    Conditions:   Cognitive Dysfunction;   Schizophrenia
    Interventions:   Drug: TC-5619;   Drug: Placebo
    Sponsor:   Targacept Inc.
    Not yet recruiting - verified October 2009

  • Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

    Conditions:   Graft-Versus-Host Disease;   Immune System Disorders
    Interventions:   Drug: Mycophenolate Mofetil;   Drug: Placebo
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
    Not yet recruiting - verified October 2009

  • A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents

    Condition:   Acute Migraine With or Without Aura in Children and Adolescents.
    Interventions:   Drug: rizatriptan benzoate;   Drug: Comparator: Placebo
    Sponsor:   Merck
    Recruiting - verified November 2009

  • Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

    Condition:   Asthma
    Intervention:   Biological: Mepolizumab (treatment) - Severe asthma
    Sponsor:   GlaxoSmithKline
    Not yet recruiting - verified November 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

    Condition:   Heart Failure
    Interventions:   Other: Daxor Blood Volume Analysis;   Other: Clinical volume status assessment
    Sponsors:   New York University School of Medicine;   Daxor Corporation
    Not yet recruiting - verified October 2009

  • Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

    Condition:   Hypertension
    Interventions:   Drug: Nebivolol;   Drug: Hydrochlorothiazide
    Sponsor:   InVasc Therapeutics, Inc.
    Recruiting - verified October 2009

  • Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

    Conditions:   Face-lift;   Facial Rhytidectomy
    Intervention:   Procedure: FS VH S/D 4 s-apr
    Sponsor:   Baxter Healthcare Corporation
    Recruiting - verified October 2009

  • EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

    Condition:   Leukemia-Lymphoma, Adult T-Cell
    Intervention:   Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified October 2009

  • A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

    Condition:   Pregnancy Prevention
    Intervention:   Drug: DR-103
    Sponsor:   Teva Women's Health
    Recruiting - verified October 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • The Women's HIV SeroIncidence Study (ISIS)

    Condition:   HIV Infections
    Intervention:  
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified June 2009

  • Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

    Condition:   Type II Diabetes Mellitus
    Interventions:   Drug: JTT-654;   Drug: JTT-654 Placebo
    Sponsor:   Akros Pharma Inc.
    Recruiting - verified November 2009

  • Red Cell Storage Duration Study

    Conditions:   Cardiac Surgery;   Erythrocyte Transfusion
    Interventions:   Biological: Red blood cell units stored <= 10 days;   Biological: Red blood cell units stored >= 21 days
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Not yet recruiting - verified October 2009

  • A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

    Condition:   Human Papillomavirus Infection
    Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
    Sponsor:   Merck
    Recruiting - verified November 2009

  • Long Term Safety and Efficacy Trial of Budesonide Dipropionate - Hydroflouroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis

    Condition:   Rhinitis, Allergic, Perennial
    Interventions:   Drug: BDP;   Drug: Placebo
    Sponsor:   Teva Global Respiratory Research LLC
    Recruiting - verified October 2009

  • Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

    Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
    Intervention:   Drug: Lenalidomide, Rituximab, and Cyclophosphamide
    Sponsors:   Emory University;   Celgene Corporation
    Not yet recruiting - verified October 2009

  • SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

    Condition:   Major Depressive Disorder
    Interventions:   Drug: SPD489 (Lisdexamfetamine dimesylate);   Drug: Matching placebo
    Sponsor:   Shire Pharmaceutical Development
    Recruiting - verified November 2009

  • Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

    Condition:   Idiopathic Parkinson's Disease
    Intervention:   Genetic: CERE-120: Adeno-Associated Virus Delivery of Neurturin
    Sponsor:   Ceregene
    Recruiting - verified November 2009

  • High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

    Condition:   Amyotrophic Lateral Sclerosis
    Interventions:   Dietary Supplement: Oxepa;   Dietary Supplement: Jevity 1.5;   Dietary Supplement: Jevity 1.0
    Sponsors:   Massachusetts General Hospital;   Muscular Dystrophy Association
    Recruiting - verified October 2009

  • Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

    Condition:   Influenza Infection
    Interventions:   Biological: GSK investigational vaccine GSK1557482A;   Biological: Fluzone®
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Subjects With Pain Due to Osteoarthritis of the Knee

    Condition:   Osteoarthritis of the Knee
    Interventions:   Drug: ADL5859;   Drug: ADL5747;   Drug: Oxycodone CR;   Drug: Placebo
    Sponsors:   Adolor Corporation;   Pfizer
    Recruiting - verified November 2009

  • Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)

    Conditions:   Type 2 Diabetes;   Hyperglycemia
    Interventions:   Drug: sliding scale regular insulin (SSRI);   Drug: Basal Bolus;   Drug: Basal Plus
    Sponsors:   Emory University;   Sanofi-Aventis;   Medical University of South Carolina;   Texas A&M University
    Not yet recruiting - verified November 2009

  • Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

    Condition:   Congenital FXIII Deficiency
    Intervention:   Drug: recombinant factor XIII
    Sponsor:   Novo Nordisk
    Recruiting - verified October 2009

  • A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

    Condition:   Schizophrenia
    Interventions:   Drug: PF-03463275;   Drug: Placebo
    Sponsor:   Pfizer
    Not yet recruiting - verified November 2009

  • A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: insulin glargine + preprandial lispro insulin;   Biological: albiglutide + insulin glargine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

    Condition:   Severe Nodular Acne
    Intervention:   Drug: CIP-Isotretinoin and Isotretinoin
    Sponsor:   Cipher Pharmaceuticals Inc.
    Recruiting - verified November 2009

  • Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

    Condition:   Castration-Resistant Prostate Cancer
    Interventions:   Drug: MDV3100;   Drug: Placebo
    Sponsor:   Medivation, Inc.
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

    Conditions:   Low Back Pain;   Low Back Pain, Recurrent
    Interventions:   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: Placebo
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain

    Condition:   Sciatica
    Interventions:   Drug: REGN475;   Drug: REGN475;   Drug: Placebo Injection
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi-Aventis
    Recruiting - verified November 2009

  • A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

    Conditions:   Osteoarthritis;   Osteoarthritis, Hip;   Osteoarthritis, Knee;   Pain;   Arthralgia;   Joint Pain
    Interventions:   Drug: JNJ-42160443;   Drug: Placebo;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443;   Drug: JNJ-42160443
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials